
    
      This is an open label, balanced, randomised, four-treatment, four-period, four-sequence,
      single oral dose, crossover Pharmacokinetics study of WD-1603 carbidopa/levodopa
      extended-release tablets in normal, healthy, adult human subjects under fed conditions. A
      single oral dose of (either Treatment A or B or C or D) carbidopa/levodopa extended release
      tablets will be administered to each subject within 5 minutes after completion of
      standardized vegetarian breakfast under fed condition in each period as per randomization
      schedule.
    
  